Back to Interventions
Substance / Medication

Clostridium histolyticum collagenase

SNOMED 56355009UMLS C0009053

Overview

Active Ingredient
collagenase Clostridium histolyticum
RxNorm CUI
898492

Indications

◊ 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 3, 4, 5, 7, 16, 19, 20, 21 Collagenase SantylOintment is indicated for debriding chronic dermal ulcersand severely burned areas.

Labeler: SMITH & NEPHEW, INCUpdated: 2019-05-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

◊ Collagenase SantylOintment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Induratio penis plastica
Skin ulcer
Burn
Dupuytren's disease of palm
Contracture of palmar fascia

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study.
García-Gómez Borja, García-Rojo Esther, Alonso-Isa Manuel et al. · Int J Impot Res · 2021
PMID: 32366987Observational
Collagenase-assisted wound bed preparation: An in vitro comparison between Vibrio alginolyticus and Clostridium histolyticum collagenases on substrate specificity.
Di Pasquale Roberta, Vaccaro Susanna, Caputo Michele et al. · Int Wound J · 2019
PMID: 31148413ObservationalFull text (PMC)
Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren's disease in 788 patients: the Austrian register.
Rohit Arora, Peter Angermann, Paul Aspalter et al. · Arch Orthop Trauma Surg · 2019
PMID: 31317303ObservationalFull text (PMC)
A quantitative structure-activity relationship study on Clostridium histolyticum collagenase inhibitors: roles of electrotopological state indices.
Gupta S P, Kumaran S · Bioorg Med Chem · 2003
PMID: 12818668Observational
Experimental immobilization of Clostridium histolyticum collagenases on green-synthesized CuO nanoparticles supported by bioinformatics analysis.
Barati Farzaneh, Hosseini Fakhrisadat, Ghadam Parinaz et al. · J Biotechnol · 2026
PMID: 41325890Other
Clostridium Histolyticum Collagenase Underdosed for Multicord Injection in Dupuytren's Disease: A Retrospective Cohort Study.
Boriani Filippo, Raggini Filippo, Evangelista Andrea et al. · Plast Reconstr Surg Glob Open · 2022
PMID: 36438471OtherFull text (PMC)
The End of an Era: Withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market.
Cocci Andrea, Russo Giorgio Ivan, Salamanca Juan Ignacio Martinez et al. · Eur Urol · 2020
PMID: 31810821Other
The Impact of Clostridium Histolyticum Collagenase on the Prevalence and Management of Peyronie's Disease in the United States.
Sun Andrew J, Li Shufeng, Eisenberg Michael L · World J Mens Health · 2019
PMID: 30588781OtherFull text (PMC)
Effect of Freeze-Dried Allograft Bone With Human Basic Fibroblast Growth Factor Containing a Collagen-Binding Domain From Clostridium histolyticum Collagenase on Bone Formation After Lumbar Posterolateral Fusion Surgery in Rats.
Inoue Gen, Uchida Kentaro, Matsushita Osamu et al. · Spine (Phila Pa 1976) · 2017
PMID: 28098745Preclinical
Enhancement of periosteal bone formation by basic fibroblast-derived growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum collagenase.
Uchida Kentaro, Matsushita Osamu, Nishi Nozomu et al. · J Tissue Eng Regen Med · 2017
PMID: 25783848Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Clostridium histolyticum collagenase (substance)
SNOMED CT
56355009
UMLS CUI
C0009053
RxNorm CUI
898492
Labeler
SMITH & NEPHEW, INC

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.